Simulations Plus (SLP) Stock Price

Simulations Plus Price

NASDAQ·CLOSED
18.40USD+0.02 (+0.11 %)
Market closed

Over the last 19 years Simulations Plus grew revenue by 14.7% annually, reaching 79.18 M USD. Earnings per share have grown at 15.0% per year over the last 18 years. For Simulations Plus, the net margin of -81.7% is down versus 21.1% a few years ago. At today's price the dividend yield works out to roughly 0.98%. The payout ratio is around 37% of earnings. The consensus 12-month price target for Simulations Plus is 24.99 USD, about 35.8% above where the stock trades today. Of 11 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 62% above its 52-week low.

Simulations Plus stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Simulations Plus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Simulations Plus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Simulations Plus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Simulations Plus Stock Price History
DateSimulations Plus Price
8/21/202618.40 USD
8/20/202618.38 USD
8/19/202618.37 USD
8/18/202618.36 USD
8/14/202618.35 USD
8/13/202618.31 USD
8/12/202618.32 USD
8/11/202618.31 USD
8/10/202618.35 USD
8/7/202618.32 USD
8/6/202618.34 USD
8/5/202618.33 USD
8/4/202618.35 USD
8/3/202618.31 USD
7/31/202618.23 USD
7/30/202618.30 USD
7/29/202618.34 USD
7/27/202618.33 USD
7/23/202618.33 USD
7/22/202618.25 USD
7/21/202618.23 USD
7/20/202618.21 USD
7/17/202618.23 USD
7/16/202618.23 USD
7/15/202618.25 USD
7/14/202618.22 USD
7/13/202618.24 USD
7/10/202618.24 USD
7/9/202618.34 USD
7/8/202618.24 USD
7/7/202618.28 USD
7/6/202618.38 USD
7/2/202618.39 USD
7/1/202618.35 USD
6/30/202618.31 USD
6/29/202618.38 USD
6/26/202618.20 USD
6/25/202618.14 USD
6/24/202618.17 USD
6/23/202618.15 USD
6/22/202618.22 USD
6/18/202618.24 USD
6/17/202618.25 USD
6/16/202618.24 USD
6/15/202616.37 USD
6/12/202616.32 USD
6/11/202616.49 USD
6/10/202615.94 USD
6/9/202616.01 USD
6/8/202615.91 USD
6/5/202615.88 USD
6/4/202616.65 USD
6/3/202616.17 USD
6/2/202616.77 USD
6/1/202617.73 USD
5/29/202617.11 USD
5/28/202616.71 USD
5/27/202615.55 USD
5/26/202615.28 USD
5/22/202615.37 USD
5/21/202615.11 USD
5/20/202614.47 USD
5/19/202614.10 USD
5/18/202613.78 USD
5/15/202613.34 USD
5/14/202613.38 USD
5/13/202613.57 USD
5/12/202613.96 USD
5/11/202614.69 USD
5/8/202616.68 USD
5/7/202616.06 USD
5/6/202615.88 USD
5/5/202615.71 USD
5/4/202615.15 USD
4/22/202615.19 USD
4/21/202615.31 USD
4/20/202614.97 USD
4/17/202614.37 USD
4/16/202614.12 USD
4/15/202614.64 USD
4/14/202613.37 USD
4/13/202612.95 USD
4/10/202613.04 USD
4/9/202612.99 USD
4/8/202613.00 USD
4/7/202612.65 USD
4/6/202612.46 USD
4/2/202611.99 USD
4/1/202611.96 USD
3/31/202611.82 USD
3/30/202611.36 USD
3/27/202611.42 USD
3/26/202611.70 USD
3/25/202611.54 USD
3/24/202611.57 USD
3/23/202611.94 USD
3/20/202611.67 USD
3/19/202611.71 USD
3/18/202611.63 USD
3/17/202611.92 USD
3/16/202612.12 USD
3/13/202612.44 USD
3/12/202612.33 USD
3/11/202612.47 USD
3/10/202612.26 USD
3/9/202612.43 USD
3/6/202612.22 USD
3/5/202612.42 USD
3/4/202612.35 USD
3/3/202611.86 USD
3/2/202612.13 USD
2/27/202612.23 USD
2/26/202612.09 USD
2/25/202611.81 USD
2/24/202611.59 USD
2/23/202611.43 USD
2/20/202611.66 USD
2/19/202612.21 USD
2/18/202612.18 USD
2/17/202612.10 USD
2/13/202612.29 USD
2/12/202612.11 USD
2/11/202612.83 USD
2/10/202613.97 USD
2/9/202614.10 USD
2/6/202614.57 USD
2/5/202614.14 USD
2/4/202614.82 USD
2/3/202615.40 USD
2/2/202616.77 USD
1/30/202616.89 USD
1/29/202617.71 USD
1/28/202618.63 USD
1/27/202619.57 USD
1/26/202620.11 USD
1/23/202620.84 USD
1/22/202620.77 USD
1/21/202620.43 USD
1/20/202620.26 USD
1/16/202620.33 USD
1/15/202620.26 USD
1/14/202619.89 USD
1/13/202619.87 USD
1/12/202618.91 USD
1/9/202619.60 USD
1/8/202618.05 USD
1/7/202618.99 USD
1/6/202619.27 USD
1/5/202619.20 USD
1/2/202618.11 USD
12/31/202518.23 USD
12/30/202518.22 USD
12/29/202518.27 USD
12/26/202518.76 USD
12/24/202519.18 USD
12/23/202519.33 USD
12/22/202519.34 USD
12/19/202518.75 USD
12/18/202518.56 USD
12/17/202518.70 USD
12/16/202518.86 USD
12/15/202519.43 USD
12/12/202519.17 USD
12/11/202519.51 USD
12/10/202519.80 USD
12/9/202519.60 USD
12/8/202519.55 USD
12/5/202519.64 USD
12/4/202520.49 USD
12/3/202520.35 USD
12/2/202519.53 USD
12/1/202517.11 USD
11/28/202517.00 USD
11/26/202517.29 USD
11/25/202517.13 USD
11/24/202517.18 USD
11/21/202517.00 USD
11/20/202516.68 USD
11/19/202516.32 USD
11/18/202516.33 USD
11/17/202516.98 USD
11/14/202517.31 USD
11/13/202517.22 USD
11/12/202517.33 USD
11/11/202517.57 USD
11/10/202517.18 USD
11/7/202517.13 USD
11/6/202517.71 USD
11/5/202517.43 USD
11/4/202517.00 USD
11/3/202516.94 USD
10/31/202517.18 USD
10/30/202517.16 USD
10/29/202517.79 USD
10/28/202518.31 USD
10/27/202518.16 USD
10/24/202517.83 USD
10/23/202517.23 USD
10/22/202517.62 USD
10/21/202515.56 USD
10/20/202516.05 USD
10/17/202515.40 USD
10/16/202516.02 USD
10/15/202515.60 USD
10/14/202515.26 USD
10/13/202515.43 USD
10/10/202514.76 USD
10/9/202515.71 USD
10/8/202516.47 USD
10/7/202516.50 USD
10/6/202516.55 USD
10/3/202516.02 USD
10/2/202515.55 USD
10/1/202515.48 USD
9/30/202515.07 USD
9/29/202514.90 USD
9/26/202514.89 USD
9/25/202514.68 USD
9/24/202514.84 USD
9/23/202515.15 USD
9/22/202515.03 USD
9/19/202515.25 USD
9/18/202515.86 USD
9/17/202515.43 USD
9/16/202515.43 USD
9/15/202514.68 USD
9/12/202515.05 USD
9/11/202514.36 USD
9/10/202513.89 USD
9/9/202514.16 USD
9/8/202514.16 USD
9/5/202513.84 USD
9/4/202514.12 USD
9/3/202514.38 USD
9/2/202514.39 USD
8/29/202514.17 USD
8/28/202514.22 USD
8/27/202514.36 USD
8/26/202513.97 USD
Access this data via the Eulerpool API
Get Free API Key

Simulations Plus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
59.58 M USD
8.73 M USD
9.96 M USD
Jan 1, 2024
70.01 M USD
6.13 M USD
9.95 M USD
Jan 1, 2025
79.18 M USD
-70.73 M USD
-64.72 M USD
Jan 1, 2026 (e)
81.96 M USD
15.30 M USD
17.19 M USD
Jan 1, 2027 (e)
86.26 M USD
16.10 M USD
18.19 M USD
Jan 1, 2028 (e)
92.60 M USD
17.29 M USD
21.31 M USD
Jan 1, 2029 (e)
103.40 M USD
19.31 M USD
25.73 M USD
Jan 1, 2030 (e)
117.10 M USD
21.86 M USD
31.36 M USD

Simulations Plus Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 8:05 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
18.0019.0024.0029.0033.0041.0046.0053.0059.0070.0079.0081.0086.0092.00103.00117.00
63.645.5626.3220.8313.7924.2412.2015.2211.3218.6412.862.536.176.9811.9613.59
72.2278.9570.8372.4172.7373.1776.0981.1379.6661.4358.2358.2358.2358.2358.2358.23
13.0015.0017.0021.0024.0030.0035.0043.0047.0043.0046.0047.1650.0853.5759.9768.13
5.007.008.0010.0010.0011.0011.0014.008.006.00-70.0015.0016.0017.0019.0021.00
27.7836.8433.3334.4830.3026.8323.9126.4213.568.57-88.6118.5218.6018.4818.4517.95
3.004.005.008.008.009.009.0012.009.009.00-64.0017.0018.0021.0025.0031.00
–33.3325.0060.00–12.50–33.33-25.00–-811.11-126.565.8816.6719.0524.00
0.200.200.210.240.240.240.240.240.240.18–0.240.240.24––
-20.00–5.0014.29–––––-25.00––––––
17.2617.4117.8618.0018.3120.8020.7520.8320.2820.2720.2220.2220.2220.2220.2220.22
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Simulations Plus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Simulations Plus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Simulations Plus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Simulations Plus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Simulations Plus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Simulations Plus stock margins

The Simulations Plus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Simulations Plus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Simulations Plus.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
77.19 %
24.22 %
21.05 %
Jan 1, 2022
79.92 %
27.66 %
23.16 %
Jan 1, 2023
80.48 %
14.64 %
16.72 %
Jan 1, 2024
61.63 %
8.76 %
14.22 %
Jan 1, 2025
58.38 %
-89.33 %
-81.74 %
Jan 1, 2026 (e)
58.38 %
18.67 %
20.97 %
Jan 1, 2027 (e)
58.38 %
18.67 %
21.09 %
Jan 1, 2028 (e)
58.38 %
18.67 %
23.01 %

Simulations Plus Stock Revenue, EBIT, Earnings per Share

The Simulations Plus earnings per share therefore indicates how much revenue Simulations Plus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.24 USD
0.54 USD
0.47 USD
Jan 1, 2022
2.59 USD
0.72 USD
0.60 USD
Jan 1, 2023
2.94 USD
0.43 USD
0.49 USD
Jan 1, 2024
3.45 USD
0.30 USD
0.49 USD
Jan 1, 2025
3.92 USD
-3.50 USD
-3.20 USD
Jan 1, 2026 (e)
4.08 USD
0.76 USD
0.86 USD
Jan 1, 2027 (e)
4.29 USD
0.80 USD
0.91 USD
Jan 1, 2028 (e)
4.61 USD
0.86 USD
1.06 USD

Simulations Plus business model & stock analysis

Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health."

Simulations Plus SWOT Analysis

Strengths

Simulations Plus Inc has established itself as a leader in the field of pharmaceutical software and consulting services.

The company has a strong reputation for providing high-quality and reliable solutions that help improve drug discovery and development processes.

Simulations Plus Inc has a diverse customer base, including leading pharmaceutical companies, regulatory agencies, and academic institutions.

Weaknesses

Despite its strong reputation, Simulations Plus Inc faces competition from other software and consulting companies operating in the same industry.

The company's reliance on a few key customers for a significant portion of its revenue poses a potential risk.

Simulations Plus Inc may face challenges in adapting to rapidly changing technological advancements in the pharmaceutical industry.

Opportunities

The increasing demand for innovative software and consulting solutions in drug development provides growth opportunities for Simulations Plus Inc.

The company can expand its market presence by targeting emerging pharmaceutical markets in regions such as Asia-Pacific and Latin America.

Collaboration with research institutions and government agencies can open avenues for new projects and partnerships.

Threats

Simulations Plus Inc may face potential threats from regulatory changes that affect the drug development and approval process.

The emergence of new competitors with advanced technology and lower pricing can pose a threat to the company's market share.

Fluctuations in exchange rates and economic instability can impact the company's international operations and profitability.

Simulations Plus Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Simulations Plus Employees
Details
Date
Simulations Plus Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Simulations Plus Segments

Simulations Plus Revenue by Segment (1/5)

  • 3 Years

  • Max

Software
Services
Consulting Services
Software Licenses
Details
Date
Software
Services
Consulting Services
Software Licenses
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
18.80 M USD
945,000.00 USD
Jan 1, 2022
32.64 M USD
21.26 M USD
0.00 USD
0.00 USD
Jan 1, 2023
36.52 M USD
23.06 M USD
0.00 USD
0.00 USD
Jan 1, 2024
41.02 M USD
28.99 M USD
0.00 USD
0.00 USD
Jan 1, 2025
45.83 M USD
33.35 M USD
0.00 USD
0.00 USD

Simulations Plus Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • Max

Software
Services
Consulting Services
Service
Software licenses
Details
Date
Software
Services
Consulting Services
Service
Software licenses
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
15.49 M USD
0.00 USD
1.05 M USD
Jan 1, 2020
0.00 USD
0.00 USD
20.00 M USD
0.00 USD
919,344.00 USD
Jan 1, 2021
27.67 M USD
0.00 USD
0.00 USD
18.80 M USD
0.00 USD
Jan 1, 2022
0.00 USD
21.26 M USD
0.00 USD
0.00 USD
1.06 M USD
Jan 1, 2023
0.00 USD
23.06 M USD
0.00 USD
0.00 USD
1.15 M USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
956,000.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
3.04 M USD

Simulations Plus Revenue by Segment (3/5)

  • Max

GastroPlus
PKPD Services
MonolixSuite TM
Medical Communications
ADMET Predictor
Other Software
QSP/QST Services
PBPK Services
Details
Date
GastroPlus
PKPD Services
MonolixSuite TM
Medical Communications
ADMET Predictor
Other Software
QSP/QST Services
PBPK Services
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
22.09 M USD
13.05 M USD
9.36 M USD
8.12 M USD
7.72 M USD
6.66 M USD
6.54 M USD
5.65 M USD

Simulations Plus Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Operating Segments
Software
Services
Simulations
Simulations Plus, Inc.
Cognigen
D I L Isym
DILIsym
Lixoft
Eliminations
Details
Date
Operating Segments
Software
Services
Simulations
Simulations Plus, Inc.
Cognigen
D I L Isym
DILIsym
Lixoft
Eliminations
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
17.55 M USD
7.86 M USD
0.00 USD
4.26 M USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
19.59 M USD
9.32 M USD
0.00 USD
5.07 M USD
0.00 USD
0.00 USD
Jan 1, 2020
41.59 M USD
0.00 USD
0.00 USD
0.00 USD
21.96 M USD
11.11 M USD
6.95 M USD
0.00 USD
1.58 M USD
0.00 USD
Jan 1, 2021
46.47 M USD
0.00 USD
0.00 USD
25.14 M USD
0.00 USD
10.55 M USD
6.12 M USD
0.00 USD
4.66 M USD
0.00 USD
Jan 1, 2022
0.00 USD
32.64 M USD
21.26 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
36.52 M USD
23.06 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
41.02 M USD
28.99 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
45.83 M USD
33.35 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Simulations Plus Revenue by Segment (5/5)

  • Max

Total Software
Total Services
Details
Date
Total Software
Total Services
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
45.83 M USD
33.35 M USD

Simulations Plus Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Americas
North And South America
North America
EMEA
Asia Pacific
Asia
Europe
South America
Details
Date
Americas
North And South America
North America
EMEA
Asia Pacific
Asia
Europe
South America
Jan 1, 2018
0.00 USD
0.00 USD
18.85 M USD
0.00 USD
0.00 USD
5.52 M USD
5.28 M USD
30,000.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
22.52 M USD
0.00 USD
0.00 USD
5.57 M USD
5.83 M USD
0.00 USD
Jan 1, 2020
0.00 USD
29.67 M USD
0.00 USD
0.00 USD
0.00 USD
6.09 M USD
5.83 M USD
0.00 USD
Jan 1, 2021
0.00 USD
32.55 M USD
0.00 USD
7.91 M USD
0.00 USD
6.01 M USD
0.00 USD
0.00 USD
Jan 1, 2022
37.68 M USD
0.00 USD
0.00 USD
10.39 M USD
5.84 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
40.82 M USD
0.00 USD
0.00 USD
11.71 M USD
7.05 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
50.47 M USD
0.00 USD
0.00 USD
14.07 M USD
5.47 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
57.70 M USD
0.00 USD
0.00 USD
14.19 M USD
7.29 M USD
0.00 USD
0.00 USD
0.00 USD

Simulations Plus Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Simulations Plus historical P/E ratio, EBIT multiple, and P/S ratio

Simulations Plus annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Simulations Plus shares outstanding

The number of shares of Simulations Plus was 20.22 M in 2025. This indicates how many shares Simulations Plus is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
20.75 M Stocks
Jan 1, 2022
20.83 M Stocks
Jan 1, 2023
20.28 M Stocks
Jan 1, 2024
20.27 M Stocks
Jan 1, 2025
20.22 M Stocks
Jan 1, 2026 (e)
20.22 M Stocks
Jan 1, 2027 (e)
20.22 M Stocks
Jan 1, 2028 (e)
20.22 M Stocks

Simulations Plus stock splits

In Simulations Plus's history, there have been no stock splits.

Simulations Plus Dividend History

13 years of dividend payments

YearAnnual DividendYoY ChangePayments
20240.18USD↓ 25.0%3×
20230.24USD 0.0%4×
20220.24USD 0.0%4×
20210.24USD 0.0%4×
20200.24USD 0.0%4×
20190.24USD 0.0%4×
20180.24USD↑ 14.3%4×
20170.21USD↑ 5.0%4×
20160.20USD 0.0%4×
20150.20USD↓ 20.0%4×

Simulations Plus dividend payout ratio

In 2025, Simulations Plus had a payout ratio of 41.85%. The payout ratio indicates the percentage of the company's profits that Simulations Plus distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
50.90 %
Jan 1, 2022
40.04 %
Jan 1, 2023
48.86 %
Jan 1, 2024
36.65 %
Jan 1, 2025
41.85 %
Jan 1, 2026 (e)
28.07 %
Jan 1, 2027 (e)
26.52 %
Jan 1, 2028 (e)
22.64 %

Current Simulations Plus forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
8.89 %
Buy
54.55 % (6)
Hold
45.45 % (5)
Sell
0.00 % (0)
12M Price Target
24.99
Last Price
18.38
Currency
USD
12M Return Potential
35.96 %
LTM Return
0 %

Simulations Plus Analyst Rating Actions

DateFirmActionRatingReliability
6/17/2026
William Blair
William Blair
DowngradeOutperformMarket Perform–
4/10/2026
TD Cowen
TD Cowen
MaintainedHold58
1/8/2026
TD Cowen
TD Cowen
MaintainedHold58
12/18/2025
BTIG
BTIG
DowngradeBuyNeutral–
7/15/2025
Stephens & Co.
Stephens & Co.
MaintainedOverweight50
7/15/2025
Keybanc
Keybanc
DowngradeOverweightSector Weight40
7/14/2025
Keybanc
Keybanc
MaintainedOverweight40
7/7/2025
BTIG
BTIG
MaintainedBuy–
6/18/2025
JMP Securities
JMP Securities
MaintainedMarket Perform–
6/13/2025
Craig-Hallum
Craig-Hallum
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Simulations Plus Earnings Calls

2025

Simulations Plus Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/9/20260.13USD-21.13 MUSD-2026 Q3
4/9/20260.20USD-21.88 MUSD-2026 Q2
1/8/20260.13USD-18.28 MUSD-2026 Q1
12/1/2025-0.05USD-17.27 MUSD-2025 Q4
4/3/20240.19USD-17.80 MUSD-2024 Q2
1/2/20240.06USD-13.71 MUSD-2024 Q1
7/4/20230.20USD-16.94 MUSD-2023 Q3
4/4/20230.18USD-16.58 MUSD-2023 Q2
1/4/20230.09USD-12.55 MUSD-2023 Q1
10/26/20220.07USD-11.09 MUSD-2022 Q4
...

EESG©

Eulerpool ESG Scorecard© for the Simulations Plus stock

48/100
32
Environment
58
Social
54
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions470.6
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees48
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Simulations Plus shareholder structure

% Name
13.89322%
FIRST LIGHT ASSET MANAGEMENT, LLC
FIRST LIGHT ASSET MANAGEMENT, LLC
7.47276%
BLACKROCK, INC.
BLACKROCK, INC.
5.32601%
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
3.68871%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
2.68182%
KENNEDY CAPITAL MANAGEMENT LLC
KENNEDY CAPITAL MANAGEMENT LLC
2.67772%
TRIBUTARY CAPITAL MANAGEMENT, LLC
TRIBUTARY CAPITAL MANAGEMENT, LLC
...

Simulations Plus Beneficial Ownership Filings (SEC 13D/G)

Free Float
83.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
13.15%
First Light Asset Management, LLC
First Light Asset Management, LLC
SEC ↗
12.00%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
12.00%
2
2
SEC ↗
11.95%
Conestoga Capital Advisors
Conestoga Capital Advisors
SEC ↗
8.33%
Neuberger Berman Investment Advisers LLC
Neuberger Berman Investment Advisers LLC
SEC ↗
8.33%
Neuberger Berman Group LLC
Neuberger Berman Group LLC
SEC ↗
7.61%
Conestoga Small Cap Fund
Conestoga Small Cap Fund
SEC ↗
5.94%
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
SEC ↗
5.80%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
5.65%
Neuberger Berman Genesis Fund
Neuberger Berman Genesis Fund
SEC ↗

Simulations Plus Executives and Management Board

16 members · avg. age 59 · 31 % women

SO

Mr. Shawn O'Connor (65)

Chief Executive Officer

1.66 M USD

Management

WF

Mr. William Frederick (62)

Chief Financial Officer, Executive Vice President

1.01 M USD
JF

Ms. Jill Fiedler-Kelly (56)

Interim President - Services Solutions

722,102.00 USD
JD

Mr. John Dibella (45)

Chief Revenue Officer

661,624.00 USD
SC

Mr. Steven Chang (56)

Global Head - Strategic Alliances

656,414.00 USD
JF

Mr. Josh Fohey

Chief Operating Officer

–
MA

Mr. Murry Alper (54)

Global Head - Medical Communications

–

Board of Directors

DW

Dr. Daniel Weiner (74)

Non-Executive Chairman of the Board

210,071.00 USD
JP

Dr. John Paglia (57)

Independent Director

200,071.00 USD
HW

Dr. Hon. Walter Woltosz (79)

Independent Director · since 1996

200,071.00 USD
LL

Dr. Lisa Lavange (71)

Independent Director

190,071.00 USD
SE

Ms. Sharlene Evans (60)

Independent Director

187,571.00 USD

Simulations Plus Supply Chain

Simulations Plus Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
12 companies
#NameTrend
1
Hangzhou Tigermed H
Customer·CN
-0.17
0.63
0.57
0.38
0.20
—
2
Dassault Systemes
Supplier·Customer·Software·FR
-0.16
0.51
0.25
0.43
0.31
-0.67
3
Eurofins Scientific
Customer·Life Sciences Tools & Services·LU
0.43
0.60
0.68
0.57
0.10
-0.65
4
Thermo Fisher Scientific
Customer·Life Sciences Tools & Services·US
0.74
0.81
0.65
0.54
0.09
-0.62
5
Lonza Group
Customer·Life Sciences Tools & Services·CH
-0.32
0.86
0.43
0.46
0.19
-0.57

Frequently asked questions about Simulations Plus

Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.

The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.

The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.

Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.

Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.

Simulations Plus Inc is primarily present in the United States.

Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.

Analysts currently set an average price target of 25.25 USD for the Simulations Plus stock (median: 24.99 USD), implying +37.4 % versus the latest price. The consensus is based on 11 analyst ratings.

Simulations Plus Analyst Price Targets 2026

11 analysts currently rate the Simulations Plus stock: 6 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Simulations Plus to generate revenue of 81.96 M USD and earnings per share of 0.85 USD.

Simulations Plus Analyst Price Targets 2026

Converted at the current exchange rate, the Simulations Plus share trades at 15.77 EUR (18.40 USD).

The Simulations Plus share (SLP) is listed on 1 stock exchanges, including: NASDAQ (SLP).

Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.

The expected revenue of Simulations Plus is 81.96 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Simulations Plus is 17.19 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Simulations Plus is currently 21.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Simulations Plus stock.

The price-to-sales ratio (P/S) of Simulations Plus is currently 4.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Simulations Plus stock.

The Eulerpool Quality Score for Simulations Plus is 3/10.

The ISIN of Simulations Plus is US8292141053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Simulations Plus is 924294. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Simulations Plus is SLP. The ticker symbol is used to trade Simulations Plus shares on the stock exchange.

Over the past 12 months, Simulations Plus paid a dividend of 0.18 USD . This corresponds to a dividend yield of about 0.98 %. For the coming 12 months, Simulations Plus is expected to pay a dividend of 0.24 USD.

The current dividend yield of Simulations Plus is 0.98 %.

Simulations Plus pays a dividend, distributed in the months of , , , .

Simulations Plus paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.24 USD are expected. This corresponds to a dividend yield of 1.30 %.

Simulations Plus is assigned to the 'Health' sector.

To receive the latest dividend of Simulations Plus from amounting to 0.06 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Simulations Plus distributed 0.24 USD as dividends.

The dividends of Simulations Plus are distributed in USD.

All fundamentals and in-depth analysis of Simulations Plus

Our stock analysis for Simulations Plus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Simulations Plus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Simulations Plus Stock
Simulations Plus Revenue→
Simulations Plus Stock
Simulations Plus Net Income→
Simulations Plus Stock
Simulations Plus P/E→
Simulations Plus Stock
Simulations Plus P/S→
Simulations Plus Stock
Simulations Plus EBIT→
Simulations Plus Stock
Simulations Plus Dividend→
Simulations Plus Stock
Simulations Plus Directors Dealings→
Simulations Plus Stock
Simulations Plus Stocks→
Simulations Plus Stock
Simulations Plus Market capitalization→
Simulations Plus Stock
Simulations Plus Debt→
Simulations Plus Stock
Simulations Plus Liabilities→
Simulations Plus Stock
Simulations Plus Equity→
Simulations Plus Stock
Simulations Plus AAQS→
Simulations Plus Stock
Simulations Plus Employees→
Simulations Plus Stock
Simulations Plus ROE→
Simulations Plus Stock
Simulations Plus ROA→
Simulations Plus Stock
Simulations Plus ROCE→
Simulations Plus Stock
Simulations Plus News→
Simulations Plus Stock
Simulations Plus Analyst Price Targets→

Health Stocks

Sincere CoSimcere Pharmaceutical GroupSinco Pharmaceuticals HoldingsSiloam International Hospitals Tbk PTSinew PharmaSilo PharmaSingapore Paincare HoldingsSillaJenSingular Health GroupSilk Laser AustraliaSinil Pharmaceutical CoSilence TherapeuticsAll Stocks A–Z →